THERAPY DOSSIER · th-51d509fb3147

Elezanumab (ABT-555), human monoclonal antibody against Repulsive Guidance Molecule A

Biologic · Repulsive guidance molecule A inhibitor (INHIBITOR, direct interaction)

Evidence & regulatory context

Mechanism: Repulsive guidance molecule A inhibitor (INHIBITOR, direct interaction)
Target: CHEMBL4630886 (repulsive guidance molecule A, RGMa)
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL4297743 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: ABT-555; AE12-1Y-QL; PR-1432051
Note: Not recorded

Clinical trials 7

2 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04295538 ↗Injury indicationPHASE2completed

Elezanumab in acute traumatic cervical spinal cord injury (proof of concept)

Spinal Cord Injury

Enrolment: 60 · Results not recorded

NCT04278235 ↗Injury indicationPhase not recordedno longer available

Expanded Access to Elezanumab

Acute Spinal Cord Injury

Enrolment not recorded · Results not recorded

NCT03737812 ↗PHASE2completed

Elezanumab added to standard of care in progressive multiple sclerosis

Multiple Sclerosis

Enrolment: 123 · Results not recorded

NCT04309474 ↗PHASE2completed

Elezanumab in acute ischemic stroke (proof of concept)

Acute Ischemic Stroke

Enrolment: 121 · Results not recorded

NCT03737851 ↗PHASE2completed

Elezanumab added to standard of care in relapsing multiple sclerosis

Multiple Sclerosis

Enrolment: 208 · Results not recorded

NCT02606630 ↗PHASE1terminated

[C-11]-PBR28 PET study of ABT-555 effect on CNS inflammation in relapsing MS

Multiple Sclerosis

Enrolment: 4 · Results not recorded

NCT02601885 ↗PHASE1completed

Escalating multiple dose study of ABT-555 in relapsing multiple sclerosis

Multiple Sclerosis

Enrolment: 20 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32590037 ↗2020Reported benefit

Delayed administration of the human anti-RGMa monoclonal antibody elezanumab promotes functional recovery including spontaneous voiding after spinal cord injury in rats.

RatSpinal cord injuryCompressionWistarFemaleIntravenousAcutely, or at 3 h or 24 h post-injury

Model: Thoracic clip impact-compression spinal cord injury

Acute and 3 h delayed intravenous elezanumab improved locomotion, fine motor function and gait, reduced lesion area, increased neuronal sparing and axonal plasticity, and produced earlier spontaneous voiding with less bladder wall hypertrophy; the 24 h group trended better with significantly greate…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…